Radiopharm Theranostics Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RADX Nasdaq 2834 www.radiopharmtheranostics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Radiopharm Theranostics Limited

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting - Sep 14th, 2026 6:00 am
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma - Sep 9th, 2026 5:00 am
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors - Aug 26th, 2026 5:00 am
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - Aug 20th, 2026 5:00 am
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases - Aug 17th, 2026 5:30 am
RADX: RAD101 Topline & FY:26 Cash Flows - Aug 3rd, 2026 9:14 am
Radiopharm Theranostics Reports Business Update - Jul 31st, 2026 5:00 am
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan - Jul 24th, 2026 5:15 am
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy - Jul 22nd, 2026 5:05 am
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases - Jul 22nd, 2026 5:00 am
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Apr 29th, 2026 6:35 am
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference - Apr 29th, 2026 3:04 am
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs - Apr 28th, 2026 11:29 am
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - Apr 23rd, 2026 6:35 am
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 - Apr 20th, 2026 5:00 am
Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases - Apr 16th, 2026 5:00 am
Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial - Apr 8th, 2026 5:00 am